Offer Request Form

Order list is empty

Shikari® (S-ATPAL) Anti-Palivizumab ELISA w/confirmation

Enzyme immunoassay for the quantitative determination (screening) of antibodies to Palivizumab (Synagis®) in serum and plasma with confirmation.

This kit has been especially developed for the quantitative determination of antibodies to palivizumab in serum and plasma samples.

Palivizumab (Synagis®) was associated to the development of anti-Palivizumab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Synagis®. This might lead to severe complications. This kit can be efficiently used for monitoring anti-Palivizumab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-Palivizumab antibodies.  

All SHIKARI® ELISA kits are suitable for biosimilar work.

All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.

For technical inquiry, please contact


Required Volume (µl) 5
Total Time (min) 140
Sample Serum, plasma
Sample Number 96
Detection Limit (ng/mL) 18,75
Spike Recovery (%) Between 85-115
Shelf Life (year) 1
Assay type Quantitative
Species Reactivity Human
Storage conditions Store at +4°C. Please refer to protocols.
Shipping conditions At room temperature
# File Action
Instructions For Use Download
Safety Data Sheet (SDS) Download
Validation Report Download

Publications with this drug

# File Action